Natural Alternatives International Q4 sales rise on royalty income
Natural Alternatives International Q4 sales rise on royalty income
Overview
US nutritional supplements maker's fiscal Q4 sales rose 1.9% yr/yr
Company posted wider net loss due to $10.4 mln non-cash impairment charge
Company consolidating US manufacturing and reviewing strategic alternatives, including possible sale
Outlook
Company plans to consolidate U.S. manufacturing into Vista, CA facility to reduce costs and boost utilization
Natural Alternatives International is exploring strategic alternatives, including possible mergers, acquisitions, or a sale
Company expects facility sales to provide liquidity, reduce debt, and eliminate excess manufacturing capacity
Result Drivers
IMPAIRMENT CHARGE - Net loss included $10.4 mln non-cash charge for underutilized Carlsbad, CA facility
PRIVATE-LABEL SALES - Private-label contract manufacturing sales rose 0.6%, driven by increased orders from one large customer, partly offset by reduced orders from others
CARNOSYN REVENUE - CarnoSyn beta-alanine royalty, licensing and raw material sales revenue rose 22% due to increased raw material sales and royalty income
Company press release: ID:nGNX5BVJWf
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Sales |
| $34.51 mln |
|
Q4 Net Loss |
| $13.54 mln |
|
Q4 Gross Profit |
| $1.73 mln |
|
Q4 Operating Income |
| -$13.18 mln |
|
Q4 Pretax Loss |
| $13.49 mln |
|
Reuters Recommended Reads
Sept 28 - Northern Star rejects Gold Fields' $27 billion bid to create world's No.2 gold miner
Sept 28 - Merck licenses SciBrunch cancer drug in deal worth up to $2.13 billion
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)